CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) Neuropsychology Assessment Battery: 35 Years and Counting
Journal of Alzheimer's Disease · 02.05.2023 · 93 (1) · 1-27
DOI: 10.3233/jad-230026 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 02.05.2023. Verfasst von Gerda G Fillenbaum und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 207 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
In 1986, the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) was mandated to develop a brief neuropsychological assessment battery (CERAD-NAB) for AD, for uniform neuropsychological assessment, and information aggregation. Initially used across the National Institutes of Aging-funded Alzheimer’s Disease Research Centers, it has become widely adopted wherever information is desired on cognitive status and change therein, particularly in older populations.
Objective
Our purpose is to provide information on the multiple uses of the CERAD-NAB since its inception, and possible further developments.
Methods
Since searching on “CERAD neuropsychological assessment battery” or similar terms missed important information, “CERAD” alone was entered into PubMed and SCOPUS, and CERAD-NAB use identified from the resulting studies. Use was sorted into major categories, e.g., psychometric information, norms, dementia/differential dementia diagnosis, epidemiology, intervention evaluation, genetics, etc., also translations, country of use, and alternative data gathering approaches.
Results
CERAD-NAB is available in ∼20 languages. In addition to its initial purpose assessing AD severity, CERAD-NAB can identify mild cognitive impairment, facilitate differential dementia diagnosis, determine cognitive effects of naturally occurring and experimental interventions (e.g., air pollution, selenium in soil, exercise), has helped to clarify cognition/brain physiology-neuroanatomy, and assess cognitive status in dementia-risk conditions. Surveys of primary and tertiary care patients, and of population-based samples in multiple countries have provided information on prevalent and incident dementia, and cross-sectional and longitudinal norms for ages 35–100 years.
Conclusion
CERAD-NAB has fulfilled its original mandate, while its uses have expanded, keeping up with advances in the area of dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, USA.
- Global Alzheimer's Platform Foundation, Washington, DC, USA.
Förderung
- NIA NIH HHS
Zitieren
APA
Fillenbaum, G. G., & Mohs, R. (2023). CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) Neuropsychology Assessment Battery: 35 Years and Counting. Journal of Alzheimer's Disease, 93(1), 1-27. https://doi.org/10.3233/jad-230026
Vancouver
Fillenbaum GG, Mohs R. CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) Neuropsychology Assessment Battery: 35 Years and Counting. Journal of Alzheimer's Disease. 2023;93(1):1-27. doi:10.3233/jad-230026
BibTeX
@article{Fillenbaum2023,
author = {Fillenbaum, Gerda G and Mohs, Richard},
title = {CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) Neuropsychology Assessment Battery: 35 Years and Counting},
journal = {Journal of Alzheimer's Disease},
year = {2023},
volume = {93},
number = {1},
pages = {1--27},
doi = {10.3233/jad-230026}
}
EUVIMED